Compare Nutrien Ltd (NTR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Revvity Inc — how do they compare? Nutrien Ltd trades at $80.95 (market cap $38.47B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Nutrien Ltd is far larger — about 2.7× Revvity Inc's market cap, and Nutrien Ltd pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| NTR | RVTY | |
|---|---|---|
Market Cap | $38.47B | $14.18B |
Sector | Basic Materials | Technology |
52-Week High | $83.94 | $130.94 |
52-Week Low | $53.64 | $82.26 |
Enterprise Value | $50.28B | $16.50B |
Dividend Yield | 2.73% | 0.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $80.68, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, driven by higher fertilizer prices. Analyst consensus is a Moderate Buy with a $76.17 price target, though recent news includes a downgrade to Hold citing cost pressures and volume constraints. Cash flow trends show consistent operational strength but negative net cash flow in recent years.
The outlook is cautiously optimistic, supported by strong potash and nitrogen demand and institutional buying, but risks include cyclical earnings, rising sulfur costs, and volatile agricultural markets. The stock's current price above the consensus target suggests limited near-term upside, requiring monitoring of cost management and volume recovery for sustained growth.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
